Could a nitric oxide mist fight tough lung infections?
NCT ID NCT06663176
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new inhaled nitric oxide treatment (RESP30X) in 60 adults with non-cystic fibrosis bronchiectasis who have stubborn lung infections like Pseudomonas. The main goals are to check safety and how well the body tolerates the mist, while also seeing if it can reduce bacteria in the lungs. Participants will receive the treatment and be monitored for side effects and changes in infection levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-CYSTIC FIBROSIS BRONCHIECTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ARENSIA Exploratory Medicine
Kyiv, Ukraine
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A vibrating vest may help children with damaged lungs breathe easier
- Can a new biologic drug delay dangerous lung Flare-Ups?
- Inhaled experimental drug targets tough lung infections
- New drug trial aims to tame chronic lung infections
- Scientists develop risk score to forecast bronchiectasis attacks
- 500 patients to test if daily azithromycin keeps bronchiectasis attacks at bay